{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:56:53Z","timestamp":1790812613805,"version":"4.1.0"},"reference-count":0,"publisher":"American Society of Hematology","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>We report the results from a Phase 1 study (NCT04557150) evaluating subcutaneous (SC) forimtamig, a novel GPRC5DxCD3 bispecific antibody with a 2:1 configuration, in relapsed\/refractory multiple myeloma (RRMM). After dose-escalation, backfilling at optimized target doses in combination with weekly (step-up: Cycle [C] 1 Day [D] 1 and C1D8; target: C1D15) and condensed (step-up: C1D1 and C1D4; target: C1D8) step-up dosing was pursued for benefit-risk assessment. Primary objectives were evaluating safety\/tolerability and determining the maximum tolerated dose (MTD) and recommended Phase 2 dose\/schedule. Secondary objectives included pharmacokinetics, immunogenicity and anti-tumor activity. In total, 171 patients were enrolled (median age: 64.0 years; high-risk cytogenetics: 32.2%; triple-class refractory: 60.2%). The starting C1D1 dose was 0.05 mg. Dose-limiting toxicities occurred in 20 patients (11.7%). MTD was not identified. Dose-escalation concluded at 7.2 mg target dose due to accumulating toxicity. The most common adverse event (AE) was cytokine release syndrome (75.4%). Grade 5 AEs occurred in 11 patients (6.4%); two events were considered treatment-related. Across all cohorts, the overall response rate (ORR) was 59.6%. At the optimized target doses (0.75 mg\/1.5 mg), ORR was 71.7% with the condensed schedule (n = 46) and 47.1% with the weekly schedule (n = 34). Early soluble B-cell maturation antigen reduction and minimal residual disease negativity were associated with improved progression-free survival. SC forimtamig demonstrated potent and durable activity in RRMM, which could be enhanced with a condensed step-up schedule. On-target, off-tumor toxicities were common, highlighting the narrow therapeutic window for GPRC5D as a target for T-cell-engaging bispecific antibodies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2026020498","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:23:21Z","timestamp":1790810601000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed\/refractory multiple myeloma"],"prefix":"10.1182","author":[{"given":"Anna Caroline","family":"Hasselbalch","sequence":"first","affiliation":[{"name":"Department of Hematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Center, Sir Peter MacCallum Department of Oncology, University of Melbourne and The Royal Melbourne Hospital, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-711X","authenticated-orcid":false,"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"CHU de Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Seoul National University College of Medicine, Korea, Republic of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6509-0578","authenticated-orcid":false,"given":"Francesco","family":"Volzone","sequence":"additional","affiliation":[{"name":"Istituto Nazionale dei Tumori \"Fondazione G Pascale\", IRCCS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"name":"CHU de Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-0085","authenticated-orcid":false,"given":"Enrique M","family":"Ocio","sequence":"additional","affiliation":[{"name":"Hospital Universitario Marques de Valdecilla (IDIVAL), Universidad de Cantabria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[{"name":"Universitair Ziekenhuis Gent, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7305","authenticated-orcid":false,"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \"Ser\u00e0gnoli\", Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[{"name":"Cancer Center Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9627-736X","authenticated-orcid":false,"given":"Christopher","family":"Parrish","sequence":"additional","affiliation":[{"name":"St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"University Hospital of Salamanca\/IBSAL\/CIC\/CIBERONC, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8605-9422","authenticated-orcid":false,"given":"Ida Bruun","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Odense University Hospital and University of Southern Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1743-8810","authenticated-orcid":false,"given":"Rodger E.","family":"Tiedemann","sequence":"additional","affiliation":[{"name":"University of Auckland and Auckland City Hospital, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[{"name":"Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea, Republic of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Sungkyunkwan University School of Medicine, Samsung Medical Center, Korea, Republic of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-7542","authenticated-orcid":false,"given":"Wolfgang","family":"Jacob","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie E.","family":"Br\u00f6ske","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Dekhtiarenko","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development (pRED), Roche Innovation Center Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rossmann","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Meneses-Lorente","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Welwyn, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4654-1131","authenticated-orcid":false,"given":"Emilie","family":"Schindler","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2888-312X","authenticated-orcid":false,"given":"Vu-Long","family":"Tran","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4676-1334","authenticated-orcid":false,"given":"Orwa","family":"Albitar","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-2398","authenticated-orcid":false,"given":"Hans-Joachim","family":"Helms","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5705-0786","authenticated-orcid":false,"given":"Nassim","family":"Sleimann","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Dimier","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Welwyn, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weisser","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[{"name":"Humanitas University and IRCCS Humanitas Research Hospital, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,30]]},"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026020498\/2593111\/bloodadvances.2026020498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026020498\/2593111\/bloodadvances.2026020498.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:23:22Z","timestamp":1790810602000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/doi\/10.1182\/bloodadvances.2026020498\/571327\/Forimtamig-a-GPRC5DxCD3-bispecific-antibody-with-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020498","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"bloodadvances.2026020498"}}